• Health Professionals
• Patients

News and Media

• Pharmaxis CEO
• Pharmaxis announces sustained benefit in cystic fibrosis following long term bronchitol treatment
• Pharmaxis provides FDA resubmission for Aridol US marketing application
• Recording of Investor Conference Call - 15 April 2010
• Pharmaxis Announces Milestone in Phase 3 Trial for Cystic Fibrosis
• Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
• Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients
• Pharmaxis completes clinical trial with the antifibrotic agent, PXS25
• Pharmaxis completes acquisition of Canadian company Topigen Pharmaceuticals Inc
• Recording of Investor Conference Call - 28 January 2010
• Conference Call Details - Quarterly Report to Shareholders and Investor Conference Call
• Pharmaxis to acquire Canadian company TOPIGEN Pharmaceuticals Inc.
• Pharmaxis receives response letter from the FDA on Aridol application
• Pharmaxis lodges TGA application to market Bronchitol™ for CF in Australia
• Pharmaxis Announces Sustained Benefit with Bronchitol in Phase 3 Cystic Fibrosis Trial

1. Pharmaxis
2. Home
3. Investors
4. News

News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles:

Copyright 2012 © Pharmaxis Ltd. All rights reserved  |  Powered by Siteflex CMS

• Sitemap
• Useful Links
• Glossary